The efficacy and safety of Trastuzumab combined with TC regimen in the treatment of HER-2 overexpressing breast cancer
WANG Xiaomei1 WANG Songzhi1 OU Jianghua2
1.Department of Pharmacy, Cancer Hospital Affiliated to Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi 830011, China;
2.Department of Breast Surgery, Cancer Hospital Affiliated to Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi 830011, China
Abstract：Objective To investigate the efficacy and safety of Trastuzumab combined with Docetaxel and Cyclophosphamide chemotherapy in the treatment of HER-2 overexpression breast cancer. Methods From October 2015 to October 2016, 79 cases of breast cancer patients in Cancer Hospital Affiliated to Xinjiang Medical University were selected. The patients were divided into the study group (38 cases) and the control group (41 cases) according to the random number table method. The control group was treated with TC combined chemotherapy before radical mastectomy. The study group was treated with Trastuzumab on the basis of control group. After 18 weeks of treatment, the curative effect and adverse reaction rate of the two groups were compared. The results of HER-2 protein, B7-H1 and IL-2 expression before and after treatment were compared. Results After treatment, the total effective rate (RR) of the study group was significantly higher than that of the control group (P < 0.05). After treatment, HER-2 overexpression rates of the two groups were significantly reduced than before treatment (P < 0.05), and the overexpression rate of the study group was significantly lower than that of the control group (P < 0.05). The positive expression rates of B7-H1 and IL-2 in the study group after treatment were significantly lower than those before treatment (P < 0.05). Adverse reactions occurred in both groups after treatment had no significant difference (P > 0.05). Conclusion Trastuzumab combined with TC regimen in the treatment of patients with HER-2 overexpression breast cancer can effectively reduce the expression of HER-2 protein, B7-H1 and IL-2, improve the clinical curative effect, which can not increase the risk of medication.
王晓梅1 王松芝1 欧江华2. 曲妥珠单抗联合TC方案治疗HER-2过度表达乳腺癌的效果及安全性[J]. 中国医药导报, 2018, 15(11): 104-107.
WANG Xiaomei1 WANG Songzhi1 OU Jianghua2. The efficacy and safety of Trastuzumab combined with TC regimen in the treatment of HER-2 overexpressing breast cancer. 中国医药导报, 2018, 15(11): 104-107.
[1] 陈万青，郑荣寿.中国女性乳腺癌发病死亡和生存状况[J].中国肿瘤临床，2015，42（13）：668-674.
[2] 赵毅，邓鑫.乳腺癌分子分型与治疗策略[J].中国实用外科杂志，2015，35（7）：704-708.
[3] Kim J，Pareja F，Weigelt B，et al. Prediction of Trastuzumab Benefit in HER-2-Positive Breast Cancers： Is It in the Intrinsic Subtype？ [J]. J Natl Cancer Inst，2017，109（2）：1.
[4] 张杰，董凤萍，汤晗，等.多西他赛联合环磷酰胺化疗方案治疗乳腺癌合并免疫系统疾病4例的病例报道[J].肿瘤药学，2016，6（3）：230-233.
[5] Swain S M，Baselga J，Kim SB，et al. Pertuzumab，trastuzumab，and docetaxel in HER-2-positive metastatic breast cancer [J]. N Engl J Med，2015，372（8）：724-734.
[6] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范（2013版）[J].中国癌症杂志，2013，23（8）：637-684.
[7] 陈梦云，高婉婉，许奕荟，等.HER-2相关基因的检测对于乳腺癌诊断及治疗中的意义[J].现代肿瘤医学，2015， 23（18）：2701-2705.
[8] Quandt D，Jasinski-Bergner S，Müller U，et al. Synergistic effects of IL-4 and TNF-α on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation [J]. J Transl Med，2014，12（1）：151.
[9] 罗年安，屈亚琦，董瑞.乳腺癌的治疗进展[J].现代生物医学进展，2015，15（1）：160-162.
[10] DeSantis CE，Fedewa SA，Goding Sauer A，et al. Breast cancer statistics，2015： Convergence of incidence rates between black and white women [J]. CA Cancer J Clin，2016，66（1）：31-42.
[11] Miller KD，Siegel RL，Lin CC，et al. Cancer treatment and survivorship statistics，2016 [J]. CA Cancer J Clin，2016， 66（4）：271-289.
[12] 宣雯霞，郭泰，王伏生.乳腺癌的治疗进展[J].中国药物与临床，2015，15（2）：203-205.
[13] 张钢龄，张培礼，朱敬军，等.紫杉醇联合卡铂单周新辅助化疗加曲妥珠单抗在HER-2阳性乳腺癌的探讨[J].中国中西医结合外科杂志，2015，21（5）：463-466.
[14] Venkatesan P. Trastuzumab emtansine for HER-2-positive breast cancer [J]. Lancet Oncol，2016，17：e528.
[15] 闫海山，张冰雁.曲妥珠单抗联合新辅助化疗用于HER2过度表达乳腺癌的临床观察[J].中国药房，2016，27（29）：4127-4130.
[16] Von MG，Procter M，De AE，et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer [J]. N Engl J Med，2017，377（2）：122.
[17] Musolino A，Naldi N，Bortesi B，et al. Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer [J]. J Clin Oncol，2016，26（11）：1789-1796.
[18] 张钢龄，张培礼，朱敬军，等.紫杉醇联合卡铂单周新辅助化疗加曲妥珠单抗在HER2阳性乳腺癌的探讨[J].中国中西医结合外科杂志，2015，21（5）：463-466.
[19] 刘鸿飞，赵帅，吴晓鎏，等.负性共刺激分子B7-H1与乳腺癌细胞化疗敏感性的关系研究[J].中国临床医生杂志，2016，44（12）：69-72.
[20] 邹小盼，郑新宇.B7同源体1和白细胞介素2在乳腺癌组织中的表达及其临床意义[J].中华乳腺病杂志：电子版，2015（4）：247-251.
2018, Vol. 15 
京公网安备 11010502046598号